Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $7
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Edward Tenthoff maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the price target from $16 to $7.
Piper Sandler analyst Edward Tenthoff maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the price target from $16 to $7.